Becton Dickinson and Co (NYSE:BDX) Position Reduced by Delta Capital Management LLC

Share on StockTwits

Delta Capital Management LLC cut its position in shares of Becton Dickinson and Co (NYSE:BDX) by 6.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,471 shares of the medical instruments supplier’s stock after selling 900 shares during the quarter. Becton Dickinson and accounts for 2.1% of Delta Capital Management LLC’s portfolio, making the stock its 26th largest position. Delta Capital Management LLC’s holdings in Becton Dickinson and were worth $3,155,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently bought and sold shares of BDX. Whittier Trust Co. lifted its position in Becton Dickinson and by 0.6% in the second quarter. Whittier Trust Co. now owns 6,982 shares of the medical instruments supplier’s stock worth $1,760,000 after purchasing an additional 40 shares during the period. ProVise Management Group LLC lifted its position in Becton Dickinson and by 2.2% in the second quarter. ProVise Management Group LLC now owns 1,902 shares of the medical instruments supplier’s stock worth $479,000 after purchasing an additional 41 shares during the period. Pitcairn Co. lifted its position in Becton Dickinson and by 1.3% in the second quarter. Pitcairn Co. now owns 3,227 shares of the medical instruments supplier’s stock worth $813,000 after purchasing an additional 41 shares during the period. Ropes Wealth Advisors LLC lifted its position in Becton Dickinson and by 0.6% in the second quarter. Ropes Wealth Advisors LLC now owns 6,801 shares of the medical instruments supplier’s stock worth $1,714,000 after purchasing an additional 43 shares during the period. Finally, Armor Investment Advisors LLC lifted its position in Becton Dickinson and by 0.5% in the second quarter. Armor Investment Advisors LLC now owns 9,265 shares of the medical instruments supplier’s stock worth $2,335,000 after purchasing an additional 44 shares during the period. 84.21% of the stock is owned by institutional investors.

Shares of NYSE BDX traded up $5.67 during midday trading on Friday, reaching $254.21. 436,470 shares of the company traded hands, compared to its average volume of 1,005,967. The firm has a market cap of $66.00 billion, a PE ratio of 23.09, a PEG ratio of 1.56 and a beta of 1.12. The stock’s 50-day simple moving average is $253.65 and its 200-day simple moving average is $245.78. Becton Dickinson and Co has a 12 month low of $208.62 and a 12 month high of $264.74. The company has a debt-to-equity ratio of 0.84, a quick ratio of 0.67 and a current ratio of 1.09.

Becton Dickinson and (NYSE:BDX) last announced its earnings results on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.05 by $0.03. Becton Dickinson and had a return on equity of 14.78% and a net margin of 5.02%. The company had revenue of $4.35 billion during the quarter, compared to analyst estimates of $4.37 billion. During the same period last year, the company posted $2.91 earnings per share. The firm’s quarterly revenue was up 1.7% compared to the same quarter last year. On average, equities research analysts expect that Becton Dickinson and Co will post 11.68 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Monday, September 30th. Stockholders of record on Monday, September 9th were paid a $0.77 dividend. The ex-dividend date was Friday, September 6th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.21%. Becton Dickinson and’s dividend payout ratio (DPR) is presently 27.97%.

Several research analysts recently commented on the company. Morgan Stanley raised their target price on Becton Dickinson and from $250.00 to $261.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 16th. Raymond James raised their target price on Becton Dickinson and from $265.00 to $288.00 and gave the stock a “strong-buy” rating in a research report on Friday, June 28th. Piper Jaffray Companies reduced their target price on Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. ValuEngine cut Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Wells Fargo & Co lifted their price objective on Becton Dickinson and from $270.00 to $290.00 and gave the company an “outperform” rating in a report on Friday, September 6th. Five research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Becton Dickinson and presently has an average rating of “Buy” and an average price target of $266.55.

In other news, CEO Vincent A. Forlenza sold 11,532 shares of the firm’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $260.38, for a total value of $3,002,702.16. Following the completion of the sale, the chief executive officer now directly owns 218,671 shares in the company, valued at $56,937,554.98. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Claire Fraser sold 1,429 shares of Becton Dickinson and stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $243.26, for a total value of $347,618.54. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 37,249 shares of company stock valued at $9,616,803. 0.12% of the stock is currently owned by corporate insiders.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

See Also: What is the Producer Price Index (PPI)?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.